ARN-509

DRUG6 trials

Conditions

Androgen AntagonistsHealthyNeoadjuvant TherapyProstate CancerProstatectomy

Phase 1

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

CompletedNCT01792687

Aragon Pharmaceuticals, Inc.Prostate Cancer

Start: 2013-02-05End: 2024-02-13Updated: 2025-03-04

14C-ARN-509 Microtracer Label AME and Absolute BA Study

CompletedNCT01822041

Aragon Pharmaceuticals, Inc.Healthy

Start: 2013-03-31End: 2013-06-30Updated: 2013-09-13

Phase 2

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

CompletedNCT01790126

Aragon Pharmaceuticals, Inc.Prostate Cancer

Start: 2013-03-04End: 2019-03-01Updated: 2020-03-11

AASUR in High Risk Prostate Cancer

CompletedNCT02772588

Memorial Sloan Kettering Cancer CenterProstate Cancer

Start: 2016-05-12End: 2026-01-22Updated: 2026-04-13

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

Active, not recruitingNCT03080116

Universitaire Ziekenhuizen KU LeuvenAndrogen Antagonists, Neoadjuvant Therapy, Prostate Cancer +1

Start: 2019-03-28End: 2024-07-01Updated: 2024-07-03

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

CompletedNCT03098836

Daniel George, MDProstate Cancer

Start: 2017-07-10End: 2024-07-09Updated: 2025-09-12

Cancer2026-05-26

Abstract LB246: Neoadjuvant androgen signaling inhibition promotes the emergence of mixed basal/club-like cancer identity cells in prostate cancer tumors

Cancer Research2026-04-17

Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.

Journal of Clinical Oncology2025-05-28

Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.

Journal of Clinical Oncology2025-05-28

Final oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.

Journal of Clinical Oncology2025-02-101 citations

Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2024-06-013 citations

Abstract 7568: Molecular effects of neo-adjuvant hormone therapy for locally advanced prostate cancer: An ancillary study of the ARNEO phase 2 trial

Cancer Research2024-03-22

Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial.

2023-10-057 citations

FRI475 The Impact Of Suppression Of Androgen Signaling On Thyroid Hormone Homeostasis In Prostate Cancer Patients

Journal of the Endocrine Society2023-10-01

A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Journal of Clinical Oncology2023-06-013 citations

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

Prostate Cancer2022-09-2816 citations

Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).

Journal of Clinical Oncology2021-05-204 citations

A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC).

Journal of Clinical Oncology2020-02-19

Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients.

Journal of Clinical Oncology2019-05-201 citations

Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa).

Journal of Clinical Oncology2018-05-201 citations

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial

BMC Cancer2018-04-0219 citations

The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.

Journal of Clinical Oncology2015-05-201 citations

ARN-509

Sponsors

Conditions

Phase 1

Phase 2

Related Papers